马萨诸塞州马尔伯勒 - 波士顿科学公司(NYSE:BSX)今天宣布，已完成对专门从事泌尿和肠道功能障碍医疗设备的Axonics公司(NASDAQ:AXNX)的收购。该交易以每股71美元的价格成交，Axonics的股权价值约为37亿美元，企业价值为33亿美元。 预计此次收购对波士顿科学2024年和2025年的调整后每股收益影响将保持中性，之后预计会产生增值效应。在GAAP基础上，由于摊销费用和收购相 ...

Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).

Boston Scientific announced the acquisition in January, but the review timeline dragged on after the Federal Trade Commission ...

Boston Scientific (BSX) announced the close of its acquisition of Axonics (AXNX). The purchase price of $71 cash per share represents an ...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a ...

Axonics (NASDAQ:AXNX) quickly edged higher by 0.8% after a Nasdaq delisting notice for its planned sale to Boston Scientific ...

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics Inc. after entering into a purchase agreement in January.

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: ...

马萨诸塞州马尔伯勒 - Boston Scientific Corporation (NYSE: BSX) 今天公布了其ACURATE IDE临床试验的主要终点结果。该试验评估了ACURATE neo2™主动脉瓣系统在各种手术风险类别的严重主动脉狭窄患者中的表现。这些发现在2024年Transcatheter Cardiovascular Therapeutics® (TCT®)研讨会上公布。 该 ...